Peter Moriarty
About Peter Moriarty
Peter Moriarty is Chief Operating Officer at Klotho Neurosciences, appointed on August 15, 2024, and was identified as a Named Executive Officer in the company’s FY2024 10‑K; the Summary Compensation Table lists him as Chief Business Officer for 2024 compensation reporting purposes . He co‑founded Shire Pharmaceuticals (later acquired by Takeda), led Prismic Pharmaceuticals as CEO (2013–2018) and Executive Chairman through its 2019 sale to FSD Pharma, and previously held leadership roles at Warner‑Lambert/Parke‑Davis, Schering‑Plough, Walsh America, and Ixsys/Applied Molecular Evolution; he founded iPhysicianNet and Clinical Information Network . Moriarty trained at Aston University School of Law and passed British Law Society qualifying exams (U.S. accredited as equivalent to a Master’s) . The company has not disclosed TSR, revenue, or EBITDA growth metrics tied specifically to his performance or compensation .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Shire Pharmaceuticals | Co‑founder | — | Created specialty pharma platform later acquired by Takeda |
| Prismic Pharmaceuticals | Chairman & CEO | 2013–2018 | Led company and positioned for exit |
| Prismic Pharmaceuticals | Executive Chairman | 2018–2019 | Led sale to FSD Pharma in 2019 |
| Warner‑Lambert/Parke‑Davis | Management positions | — | U.S. and international leadership roles |
| Schering‑Plough | Management positions | — | U.S. and international leadership roles |
| Walsh America | Head, Sales Force Automation & Software | — | Led software division; company later acquired by NDC |
| Ixsys/Applied Molecular Evolution | Corporate Development | — | Corporate development; company later acquired by Eli Lilly |
| iPhysicianNet, Inc. | Founder, Chairman & CEO | — | Founded physician‑network business |
| Clinical Information Network | Founder, Chairman & CEO | — | Founded clinical information business |
External Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Various pharmaceutical companies | Independent consultant | 2019–present | Advises pharma companies post‑Prismic exit |
Fixed Compensation
| Year | Base Salary ($) | Target Bonus (%) | Actual Bonus Paid ($) | Source |
|---|---|---|---|---|
| 2024 | 112,500 | — | 60,000 |
Notes:
- Employment agreement provides annual base salary of $300,000 effective August 15, 2024 (prorated cash paid in 2024 per Summary Compensation) and eligibility for annual bonus program; target bonus % not disclosed .
Performance Compensation
| Incentive Type | Metric(s) | Weighting | Target | Actual/Payout | Vesting | Source |
|---|---|---|---|---|---|---|
| Annual cash bonus (2024) | Not disclosed | — | Not disclosed | $60,000 cash | N/A (cash) | |
| Equity – Common shares (grants in 2024) | Service‑based vesting | — | 200,000 shares each on first and second anniversaries | Two immediate grants of 100,000 shares each (vested on grant); 400,000 shares unvested at year‑end | 200,000 on Aug 15, 2025; 200,000 on Aug 15, 2026 |
Equity Awards and Vesting Schedule (Detail)
| Grant | Type | Grant Size (shares) | Vesting Terms | Key Dates | Status at 12/31/2024 |
|---|---|---|---|---|---|
| Initial grant | Common stock | 100,000 | Vested upon grant | Aug 15, 2024 | Vested |
| Additional immediate grant | Common stock | 100,000 | Vested upon grant | 2024 (date not specified) | Vested |
| Time‑based award | Common stock | 400,000 | 50% at 1‑year; 50% at 2‑years | 200,000 on Aug 15, 2025; 200,000 on Aug 15, 2026 | Unvested (400,000) |
Equity Ownership & Alignment
| Metric | Jan 23, 2025 | Mar 26, 2025 |
|---|---|---|
| Shares Beneficially Owned | 410,904 | 410,904 |
| Ownership (% of outstanding) | 1.5% | 1.5% |
| Shares pledged as collateral | No arrangements (including pledges) that may result in change of control disclosed | No arrangements (including pledges) that may result in change of control disclosed |
Additional alignment considerations:
- Company Insider Trading Policy is on file (Exhibit 19.1), indicating governance over insider trading; specific hedging/pledging restrictions not disclosed in accessible text .
Employment Terms
| Term | Detail | Source |
|---|---|---|
| Role | Chief Operating Officer | |
| Start date | August 15, 2024 | |
| Contract term length | Three years | |
| Expiration date | August 15, 2027 | |
| Base salary (agreement) | $300,000 per year | |
| Equity in agreement | 100,000 shares (initial); 400,000 shares time‑based (200k at 1‑year; 200k at 2‑years) | |
| Annual bonus eligibility | Eligible (no specific metrics disclosed) | |
| Severance provisions | Not disclosed in accessible filings | |
| Change‑of‑control provisions | Not disclosed in accessible filings | |
| Non‑compete / non‑solicit | Not disclosed in accessible filings | |
| Clawback provisions | Not disclosed in accessible filings | |
| Auto‑renewal | Not disclosed in accessible filings |
Compensation Structure Analysis
- 2024 total compensation comprised salary ($112,500), cash bonus ($60,000), and equity awards ($660,152 grant‑date fair value), with equity the dominant component, indicating high at‑risk pay tied to service vesting rather than disclosed performance metrics .
- Equity awards emphasize retention with cliff vesting in 2025 and 2026 (200,000 shares each), potentially aligning incentives to multi‑year execution milestones; absence of disclosed performance‑conditioned PSUs/TSR metrics suggests service‑based RS grants .
Performance & Track Record
- Co‑founder of Shire Pharmaceuticals; led Prismic through sale to FSD Pharma (2019), and has sustained industry roles across U.S. and international pharma; technical and corporate development experience across multiple biopharma entities .
- Company disclosures do not attribute specific KLTO operational milestones to Moriarty in 2024–2025, nor tie his bonus to defined metrics; press releases highlight program progress but without individual executive performance linkage .
Investment Implications
- Upcoming equity vesting may create supply/insider selling pressure around August 15, 2025 and August 15, 2026 (200,000 shares each); monitor Form 4 filings and trading windows around these dates .
- Pay‑for‑performance visibility is limited: bonus eligibility is disclosed without targets/metrics, and equity appears service‑based; this reduces transparency on compensation alignment with shareholder outcomes .
- Ownership alignment is modest (1.5% of outstanding), with no disclosed pledging that could affect control; retention incentives are embedded in vesting schedule, but severance/change‑of‑control economics remain undisclosed, constraining assessment of downside protection and potential transaction incentives .
- Governance note: Insider Trading Policy exists (Exhibit 19.1), but hedging/pledging restrictions are not detailed in accessible text; lack of explicit clawback/severance terms in public sections is a diligence gap for compensation risk assessment .